抗生素暴露和新发性性结肠炎的风险:系统审查和元分析
Clinical laboratory
|October 9, 2024
概括
接触抗生素会增加患新发性性结肠炎 (UC) 的风险. 这一元分析证实了这一联系,强调需要限制不必要的抗生素使用,以防止UC.
科学领域:
- 胃肠病学 胃肠病学
- 流行病学 流行病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 以前的研究表明,抗生素暴露与性结肠炎 (UC) 发展之间存在联系,但研究结果不一致.
- 这一元分析旨在澄清抗生素暴露与UC新发病之间的关联.
研究的目的:
- 进行一项元分析,评估抗生素暴露与新发性UC的发生率之间的关联.
- 综合现有研究的证据,以确定抗生素使用是否是UC的风险因素.
主要方法:
- 在Medline和Embase数据库中进行了全面的文献搜索,截至2024年2月.
- 包含的研究使用统计方法在 Stata 软件中进行分析.
- 总共有16项研究 (12个病例控制,4个队列) 纳入了聚合分析.
主要成果:
- 分析显示,抗生素暴露与新发UC风险增加之间存在统计学上显著的关联.
- 合并的几率比 (OR) 为1.28 (95% CI = 1.26 - 1.31),表明风险增加了28%.
- 对病例控制和队列研究的子组分析支持了这一一致的发现.
结论:
- 抗生素暴露被确定为性结肠炎发展的危险因素.
- 这些发现强调了明智使用抗生素以减轻UC风险的重要性.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
147
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
147
Drugs for Treatment of Ulcerative Colitis in IBD
126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126
Peptic Ulcer Disease I: Introduction
141
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
141
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118


